STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway

Lin Jin¹,², Trung Vu¹, Guandou Yuan¹, and Pran K. Datta¹,²

Abstract

NOTCH signaling exerts essential roles in normal and malignant intestinal physiology and the homeostasis of cancer stem-like cells (CSC), but the basis for this latter role remains obscure. The signaling scaffold protein STRAP is upregulated in several cancers, where it promotes tumorigenicity and metastasis. Here we report a novel oncogenic function for STRAP in maintaining CSC subpopulations in a heterogeneous mixture by antagonizing formation of the chromatin modifier PRC2 and by epigenetically activating NOTCH signals in human colorectal cancer. Silencing STRAP sensitized colorectal cancer cells to chemotherapeutic drugs in vitro and in vivo. STRAP depletion also contributed to a reduced stem-like phenotype of colorectal cancer cells, as indicated by reduced expression of the CSC signature and NOTCH signaling regulators in vitro and by diminished tumorigenesis in vivo. Genes encoding some upstream activators of NOTCH1 were highly enriched for H3K27me3, which forms repressive chromatin domains upon STRAP silencing. Mechanistically, STRAP competitively disrupted association of the PRC2 subunits EZH2 and SUZ12, thereby inhibiting PRC2 assembly. Restoring the NOTCH pathway by lentiviral expression of NICD1 or HES1 in STRAP-depleted tumor cells reversed the CSC phenotype. In 90 colorectal cancer clinical specimens, a significant positive correlation was documented between the expression of STRAP and HES1. Overall, our findings illuminated a novel STRAP–NOTCH1–HES1 molecular axis as a CSC regulator in colorectal cancer, with potential implications to improve treatment of this disease. Cancer Res; 77(20); 1–15. ©2017 AACR.

Introduction

Colorectal cancer is the second leading cause of cancer-related deaths in the United States (1). The 5-year relative survival rate is only 8% in patients with advanced colorectal cancer despite the development of treatment regimens (2). One of the major problems hindering the advancement of colorectal cancer treatment is the presence of cancer stem-like cells (CSC), which are responsible for tumor initiation, growth, and metastasis (3). Colorectal CSCs show enhanced resistance to chemotherapy, a slow rate of cycling (4), and the capability of self-renewal, suggesting their potential role in drug resistance and tumor recurrence after initial response to chemotherapy. Therefore, therapies targeting the population of colorectal cancer CSCs can likely improve the therapeutic effectiveness of treatment (5, 6).

Current findings support that NOTCH signaling plays a crucial role in the maintenance of CSCs found in solid tumors. Upregulation of NOTCH1, JAG ligands, and HES1 in colorectal cancer cell lines results in the increased expression of the epithelial–mesenchymal transition (EMT) stemness–associated proteins CD44, SLUG, and SMAD3 (7, 8). High expression of HES1 is significantly correlated with distal metastasis at diagnosis and unfavorable prognostic outcome for patients with colorectal cancer (9). Activation of NOTCH signaling also protects CSCs from apoptosis (10). HES1 induces stem-like properties in colon cancer cells by upregulating stem cell markers at the transcriptional level (11). However, the upstream regulators of NOTCH signaling and the mechanism of their function remain unexplored.

The serine–threonine kinase receptor associated protein (STRAP) is highly expressed in several human cancers (12–14). STRAP consists of seven WD40 domains to serve as a scaffold protein (15). STRAP overexpression inhibits the antitumor effects of TGFβ (16). In addition, STRAP physically interacts with PDK1 and positively modulates its downstream targets, such as PKB/Akt and Bad, in vivo (17). Our recent studies showed that STRAP transcriptionally downregulates E-cadherin and p21Cip1 expressions (18), and it promotes the mesenchymal phenotype (19).

In this study, we demonstrate that STRAP epigenetically regulates the NOTCH pathway and maintains stem-like properties of colorectal cancer cells. Mechanistically, STRAP disassembles the PRC2 complex by disrupting the interaction between SUZ12 and EZH2, resulting in the activation of NOTCH signaling via epigenetic modification. Importantly, clinical data show that the
expression of STRAP is significantly correlated with HES1 expression. Together, our results provide a novel mechanism for the regulation of CSCs via STRAP–NOTCH1–HES1 regulatory axis.

Materials and Methods

Cell culture and reagents

Human colon adenocarcinoma cell lines—HCT116, LoVo, SW620, DLD-1, WiDr, HT29 and RKO, and HEK-293T cells—were purchased from the ATCC. Cell lines were cultured in McCoy 5A medium with 10% of FBS, and HEK-293T cells were maintained in DMEM with 10% of FBS. 5-fluorouracil (5-FU; F6627) and oxaliplatin (O9512) were obtained from Sigma-Aldrich.

Adenoviral and lentiviral transduction

STRAP-expressing adenovirus was used as described previously (13). Lentivirus constructs containing NICD1 and HES1 were obtained from Dr. Matthew Walters (Weill Cornell Medical College, New York, NY) and Dr. Linzhao Chang (Johns Hopkins University, Baltimore, MD), respectively. STRAP shRNA lentivirus was produced as described previously (13). Lentivirus shRNA targeting SUZ12 was purchased from Sigma-Aldrich.

AOM/DSS treatment of Strap+/− mice

Heterozygous knockout mice were generated using ZFN technology (20). Excision of exons 3 and 4 of the Strap gene in one allele knocks out the expression of the protein. Strap+/− mice were crossed with wild-type mice in C57BL/6 background to achieve germline transmission. Details of aoxymethane (AOM) and dextran sodium sulphate (DSS) treatment are described in the corresponding figure legend and Supplementary Material. All animal studies have been conducted in accordance with the Institutional Animal Care and Use Committee at The University of Alabama at Birmingham (Birmingham, AL).

MTT assay, colony formation, and sphere formation assays

Cells were seeded in a 96-well plate and treated with the indicated compounds for 72 hours. Cell viability was assessed using the MTT assay (Millipore). For colony formation assay, cells were suspended in agarose containing 10% FBS medium and then plated on top of semisolid agarose in 35-mm plates. Colonies were counted as described previously (13). For sphere formation assay, cell suspension in a serum-free conditioned medium was plated into an ultralow attachment 96-well plate. The conditioned medium contained DMEM/F-12 (1:1 ratio) supplemented with B27 supplement, N2 supplement, EGF, basic FGF, and insulin.

Drug-resistance assay

Six- to 8-week-old male nude mice were injected subcutaneously with stably shCtrl or shSTRAP#1 clones from HCT116 or DLD-1 cells. When tumors reached a size of about 100 mm³, the mice (8 mice/group) were treated intraperitoneally with 5-FU (50 mg/kg) or oxaliplatin (0.15 mg/kg; LC Laboratories; #O-7111) two times/week for 4 consecutive weeks. Tumor volumes at indicated time points after treatment were calculated and plotted as described previously (13).

Flow cytometric analysis

Apoptosis was evaluated using Annexin V-FITC and a propidium iodide staining kit (BD Transduction Laboratories). Flow cytometric analyses were used to detect CD133+/CD44+ cells. CD133/293C3-PE (#130-090-853) and CD44-APC (#130-098-110) antibodies (Miltenyi Biotec) were utilized to label cells.

Luciferase assays

pHES1-luc and pHES5-luc were obtained from Addgene (#43806 and #26869, respectively). All wells were also transfected with 25 ng of β-galactosidase (β-gal) as an internal control. Ratios of luciferase to β-gal readings were applied to plot the graph from triplicates values.

Immunofluorescence and immunohistochemical analyses

Cells were grown in chamber slides, fixed, and permeabilized, and then utilized to perform immunofluorescence staining with a rabbit anti-Sox2 antibody (#5797) and rabbit anti-Nanog antibody (#4903; Cell Signaling Technology) overnight at 4 °C, followed by goat anti-rabbit Alexa Fluor 488 antibody (A-11070; Life Technologies). Fluorescent cells were visualized and digital images were captured using an Olympus microscope.

For IHC analyses, paraffin-embedded tissues were incubated with the indicated antibodies. The proportion score represents the estimated fraction of stained cells (0 = 0%, 1 = 1%–24%, 2 = 25%–49%, 3 = 50%–74%, and 4 = 75%–100%), while the intensity score represents their average staining intensity (0 = no staining; 1 = weak staining; 2 = moderate staining, and 3 = strong staining). The final staining score was determined by multiplying the intensity score by the proportion score. As a result, scoring was between 0 and 12.

Quantitative PCR and ChIP assays

Quantitative (q) PCR analysis was performed as described previously (18). Purification of sonicated nuclear lysates and immunoprecipitation were performed using an EZ-ChIP assay kit (Upstate Biotechnology). The DNA samples recovered from the chromatin immunoprecipitation (ChIP) were analyzed by qPCR using specific primers (Supplementary Table S1). Primers targeting 84 genes key to the NOTCH signaling pathway were provided by the EpiTect ChIP qPCR Array kit (Qiagen).

Coimmunoprecipitation and Western blot analysis

Coimmunoprecipitation and Western blot assays were performed as described previously (18). Primary antibodies included CD133 (#18470-1-AP; Proteintech Group); ABCG2 (sc-25822) and HA (sc-805; Santa Cruz Biotechnology); CD44 (#58739) and STRAP (#611346; BD Transduction Laboratories); cleaved caspase-3 (#9661), cleaved NOTCH1 (#4147), DLL1 (#2588), DLL4 (#2589), NUMB (#2756), TACE (#6978), JAG1 (#2620), JAG2 (#2210), HES1 (#11988), OCT4 (#2840), SNAIL (#3879), SLUG (#9585), and BMI1 (#5856; Cell Signaling Technology); tri-Methyl-Histone H3 (Lys427; ab192985), SUZ12 (ab12073), EZH2 (ab3748), EED (ab169647; Abcam); and β-actin (A6316) and Flag (F3165; Sigma). For details, see Supplementary Information.

Statistical analyses

All values in the figures and text were derived from at least three independent experiments and expressed as means ± SD. Statistical analyses were completed using the SPSS statistical software package (SPSS/PC+; SPSS Inc.). Significant differences in mean
values were evaluated by the Student t test. A two-sided P < 0.05 was considered statistically significant.

**Results**

Reduced expression of STRAP enhances drug-induced apoptosis and sensitizes colorectal cancer cells to chemotherapy

Prompted by our previous studies pointing to a potential oncogenic role of STRAP (13, 14), we hypothesized that STRAP may play an important role in drug responses in colorectal cancer. MTT assays were performed to evaluate the effect of 5-FU or oxaliplatin on the survival of human colorectal cancer lines, HCT116 and DLD-1, at 72 hours posttreatment. We first knocked down (KD) STRAP expression with two independent STRAP shRNAs (shSTRAP#1 and shSTRAP#2) in these cell lines (Supplementary Fig. S1A). The shSTRAP#1 clone displayed more sensitivity to 5-FU and oxaliplatin, indicated by the lower IC_{50} values, as compared with those of the shCtrl clone (Supplementary Fig. S1B and S1C). After treatment, the percentage of apoptotic cells in the STRAP-depleted HCT116 clone was dramatically increased in response to 5-FU or oxaliplatin (10.0%–23% or 20.5%–32.2.5%, respectively) as compared with the shCtrl clone (Fig. 1A, top). An increase in apoptosis was also observed in STRAP knockdown DLD-1 cells relative to control cells (8.5%–18.3% with 5-FU; 14.4%–25.8% with oxaliplatin; Fig. 1A, bottom). Interestingly, we did not observe much effect of STRAP knockdown in both cell lines without drug treatment. In an attempt to understand the mechanism, we observed an increase in cleaved caspase-3 activity in HCT116 and DLD-1 STRAP-depleted cells (Fig. 1B) with the same treatment. Taken together, these data suggest that loss of STRAP enhances 5-FU–and oxaliplatin-induced apoptosis and sensitizes colorectal cancer cells to these drugs.

To investigate the effect of downregulation of STRAP on drug sensitivity in vivo, we treated mice bearing subcutaneous tumors generated from shCtrl and shSTRAP#1 clonal cells with 5-FU or oxaliplatin. Knockdown of STRAP alone had a significantly slower rate of growth of HCT116-derived tumors as compared with control (Fig. 1C). Mice bearing tumors from the STRAP knockdown HCT116 clone showed significant sensitivity to 5-FU or oxaliplatin when compared with those from the shCtrl clone (Fig. 1C). Similarly, we observed that knockdown of STRAP in DLD-1 cells induced sensitization to 5-FU or oxaliplatin treatment compared with the corresponding control clone (Fig. 1D). Apoptosis analyzed by active caspase-3 staining was significantly increased in 5-FU–treated shSTRAP#1 tumors relative to its parallel group (Fig. 1E; Supplementary Fig. S1D). In contrast, less staining of the proliferation marker Ki67 was observed in both untreated and treated shSTRAP#1 tumors relative to their corresponding controls (Fig. 1E; Supplementary Fig. S1D). These results provide evidence that reduced expression of STRAP potentially promotes the sensitivity of colorectal cancer cells to 5-FU or oxaliplatin-based chemotherapy.

Because of potential contributions of CSCs in drug resistance, we reasoned that STRAP may be involved in drug resistance through regulating CSCs. To assess this, we first analyzed the expressions of STRAP and CSC markers/regulators in 193 patient samples using The Cancer Genome Atlas (TCGA) mRNA-Seq colon adenocarcinoma dataset. Linear regression analyses showed that STRAP expression is significantly positively correlated with the mRNA expressions of BM1, CD24, CD44, EPCAM, ITGB1 (CD29), and PSEN1 (P < 0.0001; Fig. 1F). These genes have been proposed for the identification of colorectal CSCs (21). The upregulation of these markers is significantly correlated with invasion and metastases, and they are associated with poor prognosis (22–24). These analyses in conjunction with our above observations suggest that STRAP might play an important role in drug responses through regulating stemness of human colorectal cancer tumors.

**STRAP is important in maintaining the homeostasis of colorectal CSC pool**

To explore the potential effect of STRAP on CSCs, flow cytometry was employed to estimate the percentage of cells coexpressing CD44 and CD133 in six colorectal cancer cell lines. Expression of STRAP in each cell line after its knockdown was detected by Western blot assays (Supplementary Fig. S1E). Despite differences in the genetic profiles of the cell lines, significantly reduced expression of CD44/CD133 was observed in all shSTRAP clones (shSTRAP#1 and #2) compared with their control counterparts (Fig. 2A; Supplementary Fig. S2A). These data suggest that loss of STRAP could partly diminish the CD44+/CD133+ subpopulation in the heterogeneous mixture of cells. The next set of experiments carried out were tumor sphere assays to determine whether STRAP might regulate the self-renewal behavior of CSCs. The number of spheres in STRAP KD HCT116 and DLD-1 cells was found to be ~2-fold less than those formed in the control cells (P < 0.01; Fig. 2B and C). Furthermore, the average diameter of spheres obtained from STRAP KD cells was much less than that of control cells. It is worth noting that downregulation of STRAP almost eliminated the spheres with size ≥200 μm in both cell lines, indicating that STRAP participates into the proliferation of CSCs. Colony formation assays showed that KD cells have less proliferation potency in the anchorage-independent condition (Fig. 2D). To further ascertain that STRAP could functionally mediate the stemness of CSCs, we increased the levels of STRAP by infecting cells with adeno-virus-containing STRAP. Following the overexpression in two cell lines, there was a marked increase in sphere number and size compared with the corresponding β-gal control cells (P < 0.01; Fig. 2E).

To evaluate the effect of STRAP on tumor stem–like cells in vivo, we employed Strap⁻/⁻ mouse model and induced tumorigenicity in the colon with the carcinogen AOM and with the inflammatory agent DSS. Heterozygous deletion of Strap markedly inhibited tumor growth in mice (Fig. 2F and G). We routinely observed a decrease in STRAP expression in the intestine and colon of heterozygous mice by 60% to 70% (Fig. 2H). As reported in ref. 25, histologically, a majority of carcinomas were observed, and no metastatic lesion was evident after 10 weeks of AOM/DSS treatment (Supplementary Fig. S2B). IHC staining showed that nuclear staining of Ki67, a proliferative marker (26), was significantly reduced in Strap⁻/⁻ mice compared with those in the wild-type animals, indicating that STRAP deficiency inhibits colon carcinogenesis in mice (Fig. 2I). Interestingly, we observed less expression of CD44 and CD133 in tumors generated from Strap⁻/⁻ mice (Fig. 2I), further supporting our observations in human cell lines. Therefore, these findings suggest that STRAP is involved in CSC homeostasis and loss of STRAP results in a lower proportion of CSCs.
Figure 1.
STRAP knockdown increases the sensitivity of colorectal cancer cells to drug treatment. A, shSTRAP#1 and control clones were treated with 5-FU or oxaliplatin for 24 hours as indicated. The percentage of cells entering apoptosis was determined by flow cytometry using FITC-labeled Annexin V staining. B, Whole-cell lysates from control and STRAP knockdown clones treated with 5-FU or oxaliplatin for 48 hours were subjected to Western blot analyses using anti-cleaved caspase-3 (C.CPS) antibody with β-actin as loading control. C and D, HCT116 and DLD-1 clones (STRAP-KD and control) were implanted subcutaneously into the flank regions of nude mice. When the tumors reached 100 mm³, drug treatment was initiated. Each group consisted of eight animals. After 4 weeks, mice were euthanized, tumor volumes were measured, and growth curves were plotted. The fold changes at the bottom represent the mean change in final tumor volume of the untreated group divided by the mean tumor volume of the treated group in the same category of animals. E, Representative hematoxylin and eosin (H&E)–stained images are shown. The expression of STRAP, Ki67, and cleaved caspase-3 in the tumor from HCT116 clones was detected by IHC (magnification, ×40). F, Scatter plots of mRNA expressions (log2) of STRAP versus mRNA expression levels of BMI1, CD24, CD44, EPCAM, ITGB1, and PSEN1 in colon adenocarcinoma (n = 193) from TCGA dataset were plotted. P values and R² are displayed. Oxa, oxaliplatin.
Figure 2.
STRAP maintains stem-like phenotype of colorectal cancer cells in vitro and in vivo. A, The fraction of CD133⁺/CD44⁺ cells in stable STRAP knockdown colorectal cancer clones (WiDR, LoVo, HCT116, HT-29, RKO, and DLD-1) was analyzed by flow cytometry and plotted as percentage of positive cells. Significance levels were determined by Student t-test. n = 3; \( * \), \( P < 0.05 \); **, \( P < 0.01 \), when compared with the control. B and C, Sphere-shaped cells were generated from HCT116 shSTRAP#1 and corresponding shCtrl cells after 3 days cultured in sphere-conditioned media (left). The number and size of spheres derived from STRAP knockdown cells were compared with those of control cells (right). (Continued on the following page.)
STRAP regulates the expression of a specific subset of NOTCH signaling effectors

To understand the mechanism of STRAP-induced regulation of cancer cell stemness, we assessed the expression of diverse sets of genes: common stemness regulators such as OCT4, SOX2, NANOg, and BMI1; Zinc-finger transcription factors including SNAIL, SLUG, and TWIST; and CSC surface markers like CD44, CD133, and ABCG2. qPCR data revealed that SOX2, OCT4, BMI1, CD133, and CD44 were significantly reduced in different cell types after STRAP KD (Supplementary Fig. S3A), suggesting the deregulation of stemness-related genes by STRAP in a context-dependent manner. Western blot assays confirmed that downregulation of STRAP was able to reduce the expression of the above markers in a cell-type-specific manner (Fig. 3A). Immunofluorescence staining showed lower expression of SOX2 and NANOg in STRAP KD cells when compared with control cells (Fig. 3B and C). It has been reported that activated NOTCH signaling promotes the self-renewal capacity of colorectal CSCs (10). Here, we hypothesize that STRAP might participate in the activation of NOTCH signaling and modulate the molecular signature of colorectal CSCs. To this end, we first detected a series of genes by qPCR, including four NOTCH receptors (NOTCH 1–4) and five ligands (DLL-1, -3, -4 and -7, and JAG-1 and -2), as well as their well-documented target genes (HES1/5, HEY1/2, NRARP, and DTX; refs. 27 and 4) and JAG-1 and -2), as well as their well-documented target genes (HES1/5, HEY1/2, NRARP, and DTX; refs. 27–29). mRNA levels of JAG2, HES1, and HES5 were significantly downregulated in both KD clones as compared with their control counterparts (Fig. 3D). In addition, shSTRAP HCT116 clones showed reduced NOTCH1 and HEY1, and DLD-1 clones showed reduced DTX1 expression (Fig. 3D). Notably, NOTCH1 intracellular domain (NICD1), HES1, and JAG2 proteins were lower in shSTRAP clones as compared with the corresponding control cells (Fig. 3E; Supplementary Fig. S3B). On the contrary, there were no changes in the expressions of NOTCH ligands (DLL1/4) and NOTCH upstream regulators (ADAM9, TACE, and NUMB) in either cell line (Fig. 3E), indicating the specific effect of STRAP on selective regulation of NOTCH pathway components.

To determine the specificity of the effect of STRAP on expression of endogenous HES1, an important transcriptional regulator of NOTCH pathway, shSTRAP#1 cells were infected with adenovirus-STRAP. HES1 protein level was reduced by knockdown of STRAP, which is reversed by reexpression of adenoviral STRAP in both cell lines (Fig. 3F). Next, we investigated whether intrinsic NOTCH signaling could be inhibited through the loss of endogenous STRAP expression. Luciferase assays showed the inhibition of HES1 and HES5 promoter activity mediated by reduced level of STRAP (Fig. 3G). These results suggest STRAP involvement in the control of stemness regulators/markers in colorectal cancer cells, likely through activation of the NOTCH pathway.

STRAP helps to maintain the patterns of histone modification signature on NOTCH genes

Cumulating evidence suggests that histone modifications play a pivotal role in regulating transcriptional activity of NOTCH-related genes (30). We performed ChiP with anti-Histone H3K4me3 and H3K27me3 antibodies, followed by qPCR analyses using shCtrl and shSTRAP#1 clones in HCT116 cells. The histone modification patterns for a set of genes involved in NOTCH signaling are represented as a heatmap (Fig. 4A). We obtained 29 genes with low levels of H3K4me3 and 54 genes with H3K27me3 enrichment at the proximal promoter region (Fig. 4B). Bivalent domains bound by both H3K4me3 and H3K27me3 are found in some transcriptionally repressive genes (31). Therefore, we chose a total of 22 genes featured by increased H3K27me3 and reduced H3K4me3 levels with significant P values (Supplementary Table S2), and we performed ChiP-qPCR (Supplementary Fig. S4). Upon depletion of STRAP, the transcripts of 14 and 11 genes were downregulated in HCT116 and DLD-1 cells, respectively (Supplementary Table S3). Collectively, these results indicate that the epigenetic status of NOTCH effectors and targets could be impaired by downregulation of STRAP.

STRAP dissociates polycomb repressive complex 2 via competitive binding with SUZ12

We observed that loss of STRAP led to a remarkable distribution of H3K27me3 on the loci of NOTCH genes. We then questioned whether the global levels of H3K27me3 could also be affected by STRAP in addition to its bias on the accessibility of target gene loci. Western blot assay revealed that the total protein levels of NOTCH1 and HES1 were modestly but significantly elevated in STRAP-depleted cells (Fig. 4C; Supplementary Fig. S5A). In contrast, there is no effect of STRAP on the levels of two key subunits of PRC2 complex, SUZ12 and EZH2 (Fig. 4C; Supplementary Fig. S5A), indicating that STRAP may structurally deregulate this complex function without disrupting its subunit expression. Therefore, we were prompted to examine the possible inhibitory effect of STRAP on the PRC2 complex, which has an established role in trimethylating H3K27. Coimmunoprecipitation after coexpression of the tagged proteins in 293T cells showed that HA-tagged SUZ12 was detected in the anti-Flag immunoprecipitates. Reciprocally, Flag-tagged STRAP was also coimmunoprecipitated by the anti-HA antibody (Fig. 4D). In contrast, HA-EZH2 and HA-EED were not observed in the STRAP immunoprecipitates (Supplementary Fig. S5B and S5C). These results suggest that there is a specific...
STRAP Regulates NOTCH Pathway in Colon Carcinoma

A

<table>
<thead>
<tr>
<th></th>
<th>HCT116 shCtrl</th>
<th>DLD-1 shCtrl</th>
<th>SW620 shCtrl</th>
<th>HCT116 shSTRAP#1</th>
<th>DLD-1 shSTRAP#1</th>
<th>SW620 shSTRAP#1</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOX2</td>
<td>1.0</td>
<td>0.1</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>NANOG</td>
<td>1.0</td>
<td>0.1</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>OCT4</td>
<td>1.0</td>
<td>0.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>BMI1</td>
<td>1.0</td>
<td>0.6</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>SNAIL</td>
<td>1.0</td>
<td>0.4</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>CD133</td>
<td>1.0</td>
<td>0.2</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>ABCG2</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>CD44</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>β-Actin</td>
<td>1.0</td>
<td>1.3</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

B

C

D

HCT116

<table>
<thead>
<tr>
<th>Notch components</th>
<th>shCtrl</th>
<th>shSTRAP#1</th>
<th>shSTRAP#2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jag1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Jag2</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Dll1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Dll2</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Dll3</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Jag1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Jag2</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Notch targets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hes1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Hes2</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Dtx1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Notch targets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicd1</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Hes1</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Hes6</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>β-Actin</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

E

DLD-1

<table>
<thead>
<tr>
<th>Notch components</th>
<th>shCtrl</th>
<th>shSTRAP#1</th>
<th>shSTRAP#2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jag1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Jag2</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Dll1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Dll2</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Dll3</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Jag1</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Jag2</td>
<td>1.0</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Notch targets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hes1</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Hes2</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Dtx1</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>β-Actin</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

F

G

HCT116

<table>
<thead>
<tr>
<th>Luciferase activity</th>
<th>Hes1</th>
<th>Hes6</th>
</tr>
</thead>
<tbody>
<tr>
<td>shCtrl</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>shSTRAP#1</td>
<td>0.1</td>
<td>0.0</td>
</tr>
</tbody>
</table>

DLD-1

<table>
<thead>
<tr>
<th>Luciferase activity</th>
<th>Hes1</th>
<th>Hes6</th>
</tr>
</thead>
<tbody>
<tr>
<td>shCtrl</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>shSTRAP#1</td>
<td>0.1</td>
<td>0.0</td>
</tr>
</tbody>
</table>
interaction between STRAP and SUZ12 despite STRAP not being incorporated into a complete PRC2 complex. Indeed, endogenous STRAP protein was also coimmunoprecipitated by anti-SUZ12 antibody from HCT116 and DLD-1 cells (Fig. 4E). However, we did not observe any endogenous interaction of STRAP with either EZH2 or EED (data not shown), as mentioned above. Together, the data suggest that STRAP selectively interacts with SUZ12, and not with EZH2 and EED.

The interaction between STRAP and SUZ12 led us to examine whether STRAP affects the PRC2 complex assembly. We coexpressed proteins by cotransfecting HA-tagged EZH2 and SUZ12 together with dose-dependent Flag-tagged STRAP. As expected, SUZ12 was coimmunoprecipitated by the anti-EZH2 antibody. Interestingly, increasing STRAP overexpression greatly decreased the SUZ12 and EZH2 complex formation, with no change in their protein levels (Fig. 4F). In contrast, there was no altered interaction between EZH2 and EED upon increased STRAP expression (Fig. 4G). To further assess whether depletion of STRAP-induced reduction in HES1 depends on SUZ12, endogenous expression of HES1 was tested by a specific shSUZ12 RNA. Western blot assay showed that SUZ12 KD had a positive effect on HES1, as evidenced by a significantly increased level of HES1 in shSUZ12 cells compared with that in scrambled shRNA cells (Fig. 4H). Furthermore, restored expression of HES1 was observed in STRAP KD cells with concomitant loss of SUZ12 (Fig. 4H). Collectively, these data indicate that STRAP regulates the expression of HES1, in part through the presence of functional SUZ12, and HES1 might be a direct potential target of SUZ12 in colorectal cancer.

Loss of STRAP expression enhances PRC2 trimethyltransferase function on H3K27 at HES1 and HES5 loci

To address the functional regulation on local chromatin modification of target genes in CSCs by STRAP, we extended our studies to sphere-derived cells, which have more cancer stem-like properties than cells in adherent culture system (32). We first validated that sphere-derived cells are suitable for the CSC model based on significant enrichment of CD133+/CD44− cells. Enrichment was accompanied by enhanced activation of NOTCH signaling, with increased expression of IAG receptors and HES1 (Fig. 5A and B). Surprisingly, increased expression of STRAP was observed in sphere culture condition, especially in HCT116 and DLD-1 cells, suggesting a potential involvement of STRAP in CSC maintenance (Fig. 5B). Next, we stably knocked down STRAP using lentivirus-mediated shRNA#1 in HCT116 and DLD-1 sphere-derived cells (Fig. 5C). qPCR assay showed a significant decrease in CD133, CD44, HES1, and HES5 in KD HCT116 cells and CD133, CD44, and HES1 in KD DLD-1 cells (Supplementary Fig. S6). To closely examine the chromatin signature of STRAP target genes in these cells, two transcription factors activated by NOTCH signaling, HES1 and HES5, were chosen to perform ChIP assay (Fig. 5D). H3K27me3 is highly distributed at several binding sites on the target genes along more than 3.0 kb upstream of TSS in KD sphere-derived cells, whereas H3K4me3 showed a decreased abundance at the same sites (Fig. 5D–F). These results indicate that the two markers compete with each other to occupy the loci of HES1 and HES5, and the inactive chromatin status is controlled by H3K27me3 upon STRAP downregulation. Of note, concurrence of EZH2 and SUZ12 enrichment with H3K27me3 abundances was also observed in most target binding regions (Fig. 5E and F), further evidencing the pattern of H3K27 trimethylation on its target cis-regulatory regions.

NICD1–HES1 signaling restores the stem-like phenotype of CSCs in STRAP KD cells

Next, we conducted gain-of-function assays either with NICD1- or with HES1-lenti viral constructs to reactivate NOTCH signaling in STRAP-KD cells. Restoration of NICD1 or HES1 resulted in significantly increased mRNA levels of NOTCH target genes (e.g., HES1, HES5, and TWIST), CD133, and CD44 in a cell-dependent manner (Fig. 6A and B), suggesting that NOTCH signaling is important in STRAP-mediated regulation of stemness-related genes. Western blot assays further confirmed the restored protein expressions of CD44, CD133, and HES1 by either NICD1 or HES1 in STRAP KD cells (Fig. 6C). The differential expression of CD44 and CD133 in different cell lines at mRNA and/or protein level regulated by STRAP may take place through different mechanisms. The percentage of CD44+/CD133+ cells was significantly increased in response to NICD1 or HES1 restoration in shSTRAP cells relative to β-gal control cells (Fig. 6D). To address the concurrent biological outcomes, we compared the proliferative ability of the rescued cells with corresponding STRAP-KD cells. Both NICD1- and HES1-rescued cells showed the restoration in sphere number and size compared with the STRAP-KD groups (Fig. 6E and F). Collectively, our data suggest that activation of STRAP-induced NOTCH signaling is involved in promoting the stem-like phenotype of colorectal cancer cells.

STRAP positively correlates with the expression of HES1 in human colorectal cancer

To verify the biologic significance of NOTCH signaling activation by STRAP, we examined the correlation of expression between STRAP and HES1 in human colorectal cancer. We performed IHC analyses for STRAP and HES1 in serial sections of colon tumor microarrays containing 90 colorectal cancer patient specimens. The results showed that HES1 and STRAP are both
upregulated in the colon cancer tissues compared with normal colon tissues, with values 72.5% and 65.3%, respectively (Fig. 7A–D). We also observed that the higher score of HES1 is concomitant with that of STRAP (IHC score from 6–12) compared with the low expression group (IHC score from 0–4; 7.21 vs. 3.24; Fig. 7E–G). A statistically significant positive correlation was observed between the expressions of STRAP and HES1 in adenocarcinoma samples (Fig. 7H). Consistent with previous observations, STRAP and HES1 have been found to be present in both the nucleus and cytoplasm. Moreover, we found that the expression of both STRAP and HES1 was much higher in American Joint Committee on Cancer (AJCC) stage I than that in other stages (Fig. 7E and F), suggesting that STRAP and HES1 may coordinate function in colorectal cancer tumorigenesis. This observation is also consistent with previous studies showing that NOTCH signaling is high in early stages of human colorectal cancer (33). To further assess the clinical relevance of STRAP expression, TCGA data of 274 patients with colorectal adenocarcinoma and 41 controls were downloaded from UALCAN (http://ualcan.path.uab.edu/index.html; ref. 34). The mRNA level of STRAP was increased in all stages of colorectal cancer tissues compared with the normal tissues (Fig. 7I). The overall survival of colorectal cancer patients was significantly associated with STRAP expression (P < 0.05; Fig. 7J). The prognosis of patients with high expression of STRAP was worse than cases with low expression. Taken together, these data indicate that STRAP-induced activation of NOTCH signaling is involved in colorectal cancer progression and in maintaining cancer stem-like subpopulation.

Discussion

In this study, we observed that the variation of CSC markers based on tumor cell types and this subpopulation constitutes 0.1% to 10% (35, 36). It is important to note that the best marker/s to identify colorectal CSCs is not well defined thus far. However, the expression of putative markers for colorectal CSCs, like CD133 and CD44, are positively regulated by STRAP in a number cell types (Fig. 2A). This is supported by the result that knockdown of STRAP reduced the expression of some stem cell markers that are more frequently found in poorly differentiated tumors with poor clinical outcome (Fig. 3A–C; refs. 37, 38). Notably, mRNA of CD133 was rescued in HCT116 KD cells, and mRNA of CD44 was rescued in DLD-1 KD cells by NOTCH signaling. However, protein levels of CD133 and CD44 were upregulated in both STRAP KD cell lines (Fig. 6A–C), suggesting the involvement of a different mechanism. The role of STRAP in regulating these stem-related markers is also supported by in vivo data using heterozygous mice (Fig. 2G–I). JAG/NOTCH/HES signaling has been implicated in the regulation of cell proliferation, EMT, metastasis, stem-like phenotype, and chemoresistance. We have shown that STRAP-mediated activation of JAG2, NOTCH1, HES1, and HES5 plays an important role in colorectal cancer tumorigenicity and stemness (Figs. 3D and E and 6). This is confirmed by the restoration of stemness markers and phenotype by the expression of NICD1 or HES1 in STRAP knockdown HCT116 and DLD-1 clones (Fig. 6). As a result, STRAP KD cells are much less aggressive in terms of soft agar colony formation and sphere formation (Fig. 2B–E). Our future work will determine whether other cytokines, chemokines, and environmental alterations functionally interact with the activation of intrinsic NOTCH signaling activated by STRAP.

Our data show that the protein level of STRAP is highest in stage I and its expression is lower but similar in stages II/III/IV. However, all stage levels are significantly higher compared with normal tissues in normal tissues (Fig. 7E). The mRNA level of STRAP was increased in all stages of colorectal cancer tissues compared with normal tissues (Fig. 7I). Our data support the roles of STRAP in promoting cancer cell stem-like phenotype and in drug resistance. These observations are in agreement with a previous report that colorectal cancer patients with upregulation of STRAP had worse survival with adjuvant therapy, suggesting its vital role in chemoresistance (39). The level of STRAP did not increase in advanced stages (III/IV) from stage I, and it promotes cell proliferation in vivo (Figs. 1E and 2I). It has been shown that in patients with advanced stages of colorectal cancer, tumor cells exhibit a decreased cell proliferation that might reduce the effectiveness of chemotherapeutics, such as 5-FU and oxaliplatin, which primarily target rapidly dividing cell populations (40). A medium level of STRAP expression (not high) in advanced stages may contribute to a low level of cell proliferation, a factor important for resistance to cytotoxic drugs. In addition, the highest expression of STRAP in stage I may be involved in tumor progression. A similar expression pattern has been observed for another protein, ZBP-89, that plays an important role in colorectal cancer progression and in vivo.
maintenance of cancer cell stemness (41). Together, high expression of STRAP in different stages of colorectal cancer may be linked to tumor progression and stemness phenotype.

Loss of PRC2 function contributes to oncogenesis in leukemia and lymphoma, indicating that the component genes of PRC2 serve as tumor suppressors (42, 43). On the other hand, abnormal expressions of PRC2 genes correspond to human epithelial tumors (44, 45). Although the H3K27me3 level is not always sufficient to prevent transcriptional activation (46), PRC2-mediated H3K27 trimethylation is found remarkably in the promoter regions of inactive transcripts of NOTCH genes in STRAP KD cells. These results point to a critical role of STRAP as a positive modulator of NOTCH signaling by effectively repressing the formation of PRC2 complex in CSCs (Fig. 7K). Therefore, our data provide evidence,
for the first time, that (i) key components of PRC2 are necessary to selectively inactivate the transcription of NOTCH target genes in STRAP KD cells; (ii) upregulation of STRAP in colorectal cancer impairs the association of the complex and influences H3K27me3, a hallmark for the repression of NOTCH related genes; and (iii) EZH2 and SUZ12 might be the putative tumor suppressors in our models, depending on their activated function on target chromatin regions rather than the deregulated expression.
STRAP positively correlates with the expression of HES1 in colon tumors. A–D, Representative images for STRAP and HES1 expressions in IHC using serial sections of tissue microarrays from normal human colon (A), adenocarcinoma stage I (B), stage II (C), and stage III (D). Magnification, 100 and 400 for the insets. E and F, The weighted scores of the IHC staining for STRAP (E) or HES1 (F) plotted based on the histology. *, P < 0.05; **, P < 0.01; ***, P < 0.005. G, Tumors were divided into high STRAP IHC score (7–12) and low STRAP IHC score (0–4). The median IHC scores of HES1 were significantly different between the two groups using a two-tailed t test. ***, P < 0.001. H, The expression of STRAP and HES1 in colorectal cancer patient samples was analyzed for correlation by Spearman rank correlation coefficient analysis. R = 0.689; P < 0.0001; n = 90. I, Box plot analysis shows overexpression of STRAP in all stages of colorectal cancer versus normal tissues by RNA-Seq–derived expression data from TCGA. J, Kaplan–Meier graph shows the survival analyses of patients with colorectal cancer based on STRAP expression. The median cutoff of STRAP expression was 0.0104, which was used to differentiate high and low expression groups for survival benefits. High STRAP represents patients with individual expression of STRAP ≥ cutoff, and low STRAP represents patients with individual expression < cutoff. K, Cartoon illustration of the underlying mechanisms by which STRAP regulates the NOTCH signaling pathway via the PRC2 complex. The assembly of the PRC2 complex is impaired in the presence of STRAP, resulting in the transcriptionally active chromatin marked with the high abundance of H3K4me3 at NOTCH signaling genes. Conversely, in the absence of STRAP, the expressions of these genes are epigenetically repressed by PRC2 as a result of the enrichment of H3K27me3. CRC, colorectal cancer.
In conclusion, we show that STRAP exhibits oncogenic effects through mediating the epigenetic activation of NOTCH signaling, and is a regulator of tumor stemness behavior and drug response. In addition, the significant correlation of the expression of STRAP with HES1 and with stem markers in patients with colorectal cancer highlights its clinical importance for novel therapeutic options in colorectal cancer treatment.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: L. Jin, T. Vu, P.K. Datta

Development of methodology: L. Jin, T. Vu, G. Yuan, P.K. Datta

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Jin, P.K. Datta

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L. Jin, T. Vu, P.K. Datta

Writing, review, and/or revision of the manuscript: L. Jin, T. Vu, P.K. Datta

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Jin, P.K. Datta

Study supervision: P.K. Datta

Acknowledgments
The authors thank Dr. Sejong Bae for statistical analyses and Dr. Tasha Smith for critically reading the manuscript.

Grant Support
This work was supported by National Cancer Institute R01 CA95195, Veterans Affairs Merit Review Award and a Faculty Development Award from the UAB Comprehensive Cancer Center, P30 CA013148 (to P.K. Datta).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 28, 2017; revised July 10, 2017; accepted August 14, 2017, published OnlineFirst August 21, 2017.

References


STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway

Lin Jin, Trung Vu, Guandou Yuan, et al.

Cancer Res Published OnlineFirst August 21, 2017.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-17-0286

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2017/08/18/0008-5472.CAN-17-0286.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.